To determine the possible mechanisms underlying the efficacy of CH (OVA+poly I:C)-NP treatment in tumor tissues, we examined the tumors for markers of CD8+ T cells (anti-CD8 immunostaining), cytotoxic CD8+ T cells (anti-CD8 and anti-IFN-γ immunostaining), and myeloid-derived suppressor cells (MDSCs, anti-GR-1 and anti-CD11b immunostaining, Fig. 5D). Here, CD8A is linked to neoplasm.